The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy.
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2012
At a glance
- Drugs Paricalcitol (Primary)
- Indications Diabetic nephropathies; Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DiaZemp
- 12 Apr 2012 Actual patient number is 48 as reported by ClinicalTrials.gov.
- 12 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2011 Planned End Date changed from 1 Feb 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.